These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 14604889

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis.
    Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi DF, Asara G, Casabona D, Frau M, Seddaiu MA, Feo F.
    Hepatology; 2002 Jun; 35(6):1341-50. PubMed ID: 12029619
    [Abstract] [Full Text] [Related]

  • 3. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis.
    Liao DJ, Natarajan G, Deming SL, Jamerson MH, Johnson M, Chepko G, Dickson RB.
    Oncogene; 2000 Mar 02; 19(10):1307-17. PubMed ID: 10713672
    [Abstract] [Full Text] [Related]

  • 4. [Inhibitory effect of cyclin D1 antisense cDNA on human hepatocarcinoma cell line HepG2].
    Xiao ZY, Chen XP, Huang ZY.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct 02; 13(10):768-71. PubMed ID: 16248951
    [Abstract] [Full Text] [Related]

  • 5. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
    Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM.
    Cancer Res; 2001 Feb 01; 61(3):1178-86. PubMed ID: 11221849
    [Abstract] [Full Text] [Related]

  • 6. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
    Davis JN, McCabe MT, Hayward SW, Park JM, Day ML.
    Cancer Res; 2005 May 01; 65(9):3633-42. PubMed ID: 15867358
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells.
    Jeong Seo E, Jung Kim H, Jae Lee C, Tae Kang H, Seong Hwang E.
    Gynecol Oncol; 2004 Jul 01; 94(1):40-7. PubMed ID: 15262117
    [Abstract] [Full Text] [Related]

  • 9. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors.
    Schuldiner O, Benvenisty N.
    Oncogene; 2001 Aug 16; 20(36):4984-94. PubMed ID: 11526483
    [Abstract] [Full Text] [Related]

  • 10. Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle.
    Hengstschläger M, Hölzl G, Hengstschläger-Ottnad E.
    Oncogene; 1999 Jan 21; 18(3):843-8. PubMed ID: 9989838
    [Abstract] [Full Text] [Related]

  • 11. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
    Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, Sakamaki T, Pestell RG, Yamamoto K.
    Clin Cancer Res; 2007 Apr 01; 13(7):2236-45. PubMed ID: 17404108
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
    Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, Grassi M, Uxa L, Giansante C, Zennaro C, Guarnieri G, Grassi G.
    Biochimie; 2009 Mar 01; 91(3):373-82. PubMed ID: 19041685
    [Abstract] [Full Text] [Related]

  • 13. [Vitamin C reverses benzo (a) pyrene-induced cell cycle changes by E2F pathway].
    Gao A, Liu BC, Shen FH, Du HJ, Huang CS, Jia XW, You BR, Ye M.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2006 Mar 01; 40(2):79-83. PubMed ID: 16640900
    [Abstract] [Full Text] [Related]

  • 14. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1.
    Chen C, Chang YC, Liu CL, Chang KJ, Guo IC.
    Breast Cancer Res Treat; 2006 Jul 01; 98(2):121-32. PubMed ID: 16752079
    [Abstract] [Full Text] [Related]

  • 15. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
    Biliran H, Banerjee S, Thakur A, Sarkar FH, Bollig A, Ahmed F, Wu J, Sun Y, Liao JD.
    Clin Cancer Res; 2007 May 01; 13(9):2811-21. PubMed ID: 17473215
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ.
    Clin Cancer Res; 2005 Sep 01; 11(17):6333-41. PubMed ID: 16144938
    [Abstract] [Full Text] [Related]

  • 17. Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1.
    Swarbrick A, Akerfeldt MC, Lee CS, Sergio CM, Caldon CE, Hunter LJ, Sutherland RL, Musgrove EA.
    Oncogene; 2005 Jan 13; 24(3):381-9. PubMed ID: 15489884
    [Abstract] [Full Text] [Related]

  • 18. A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells.
    Park SE, Lee SW, Hossain MA, Kim MY, Kim MN, Ahn EY, Park YC, Suh H, Kim GY, Choi YH, Kim ND.
    Cancer Lett; 2008 Oct 18; 270(1):77-86. PubMed ID: 18554781
    [Abstract] [Full Text] [Related]

  • 19. Reduction of c-myc expression by an antisense approach under Cre/loxP switching induces apoptosis in human liver cancer cells.
    Ebinuma H, Saito H, Kosuga M, Wakabayashi K, Saito Y, Takagi T, Nakamoto N, Okuyama T, Ishii H.
    J Cell Physiol; 2001 Jul 18; 188(1):56-66. PubMed ID: 11382922
    [Abstract] [Full Text] [Related]

  • 20. Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells.
    Shehata M, Shehata M, Shehata F, Pater A.
    Cell Biol Int; 2004 Jul 18; 28(12):895-904. PubMed ID: 15566959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.